Navigation Links
Eye Drug Macugen Shows Allergic Reactions

The drug Macugen was approved by the Food and Drug Administration (FDA) to treat age-related vision loss known as macular degeneration was reported// to show serious allergic reactions. Pfizer Inc. and OSI Pharmaceuticals said that with use of their eye drug Macugen along with other medications resulted in allergic reactions. FDA says that the companies have already notified the doctors about the reactions, which included allergic swelling around the eyes or lips and other anaphylactic symptoms. After the complaints the companies have added the information about these in their drug's label.

Due to this Pfizer shares closed down 1.6 % at $24.69 on the New York Stock Exchange. Shares of OSI at 3.5 % at $30.02 on the Nasdaq. The companies also warned doctors to evaluate patients for a history of hypersensitivity reactions before giving the drug. The drug makers said that the complaints came in after the injectable drug was approved in the United States in 2004. The sensitivity occurred when Macugen (pegaptanib) was given along with other medications as part of the injection procedure.


'"/>




Page: 1

Related medicine news :

1. Macugen drug for treating degenerative eye disease
2. Experimental treatment for Ebola Virus Shows promising results in mice
3. New Prostate Cancer Vaccine Shows Promise
4. Ebola Treatment Shows Promise
5. New Drug Shows Significant Improvement In HIV-related Heart Condition
6. Greek Study Shows Living In The Hills May Be Healthier
7. Research Shows Carbon Monoxide Prevents Inflammations
8. Latest Research Shows That Multivitamins Might Not Prevent Infections In All Elderly
9. Novartis MS Drug Shows Promising Results
10. MRI Shows Emotional Changes During Menstrual Cycle
11. Bronchiolo-alveolar Carcinoma Shows Sonographic Pattern Of Pneumonia
Post Your Comments:
(Date:9/4/2008)... may be shortchanging their golden years by tappin...iversity of Illinois expert who has studied the fe..., More than three of every four Americans trim th...iming benefits early, a choice many might forego i... consequences, law professor Richard L. Kaplan say...
(Date:9/4/2008)...ncology contract research organization, has publis...uanced Approach to Get Into the Clinic Faster.&quo...al research scientist with 35 years of experience,...mmonly viewed as straightforward investigations ru...rue integration with preclinical, regulatory and c...
(Date:9/4/2008)...NORWICH, England and ONGAR, Ireland,Sept. 4 /PRNe...ofield Media,Europe Ltd, announced on the 29th Aug... publication from Silverdog Publishing., Health a... the iconic,Health and Safety at Work Act 1974 and.... It has been relied upon by blue-chip corporates,...
(Date:9/4/2008)...-FirstCall/ -- ULURU Inc. (Amex:,ULU) today announ...Weisel,Partners Healthcare Conference at 3:15 p.m....out ULURU Inc.:, ULURU Inc. is an emerging specia...ent of a portfolio of wound management, plastic su...nd consumers improved clinical,outcomes through co...
Breaking Medicine News(10 mins):Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3Health News:Schofield Publishing Enters the Newsletter Market 2
...ng to India's health sector with an approval of $6... Tuesday.// "Three projects totalling $662 million...w been approved by the board of executive director...ance ministry statement said. The approval of the...
...s of a Jharkhand girl who complained that she wept...tute of Medical Science (AIIMS) here Wednesday.// ...rkhand, has been complaining of stones in her tear...he was brought to the capital Tuesday for treatmen...
...ed by a pill according to European researchers. Th...owed the effectiveness of the Grazax allergen tabl... treated with allergy shots. Allergies are a resul... to a normally harmless substance, such as dust mi...
...a controversial licensing scheme. According to it,...ucts// will be permitted to describe the ailments ...ing homeopathic remedies into the area of licensed...s designed. However, doctors and scientists believ...
Other Medicine News:Health News:Doctors worried about Homeopathic licensing 2
(Date:9/4/2008)...e with Two Abstracts Accepted for Presentation..., BRIDGEWATER, N.J., Sept. 4 /- Aege...ical company focused on the treatment of,cardiovas...ppointment of,Peter L. Garrambone, Jr. to the Comp...eer includes more than 50 pharmaceutical,transacti...
(Date:9/3/2008)...g Children Studied. Wrong,Conclusions Reached., N...ters for Disease,Control and Prevention (CDC) stud...he MMR vaccine and autism. The National Autism Ass...pel the growing public concern over a,vaccine-auti...ing design,and methodology., For years, parents h...
(Date:9/3/2008)...Research and Education Foundation,s Within Our Re...ing, Treating and Understandin...rst time during its,unprecedented initiative to fi...ollege of Rheumatology Research and Education Foun...research funded by the Within Our,Reach: Finding a...
(Date:9/3/2008)...ar Disease Awareness Month, CHARLOTTESVILLE, Va.,...,LLC, a clinical-stage drug-development company co... medical needs, announced today that it has begun,...of its lead drug,candidate trans sodium crocetinat...clinicaltrials.gov Website, is investigating TSC a...
Breaking Medicine Technology:Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2CDC Misses Target With Flawed MMR/Autism Study 2New Research Shows Promise for Finding A Cure for Rheumatoid Arthritis 2New Research Shows Promise for Finding A Cure for Rheumatoid Arthritis 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4ABR Affinity BioReagents Participates in the 2008 Fisher Scientific Supplier Expo in San Antonio Texas 10943 1ABR Affinity BioReagents Participates in the 2008 Fisher Scientific Supplier Expo in San Antonio Texas 10943 2ATS Medical Expects Fourth Quarter Revenue to Increase by Approximately 32 25 10941 1ATS Medical Expects Fourth Quarter Revenue to Increase by Approximately 32 25 10941 2Rochester Medical Reports 31 25 Increase in Branded Sales Resulting in 9 25 Overall Sales Growth for the First Quarter 2991 1Rochester Medical Reports 31 25 Increase in Branded Sales Resulting in 9 25 Overall Sales Growth for the First Quarter 2991 2Rochester Medical Reports 31 25 Increase in Branded Sales Resulting in 9 25 Overall Sales Growth for the First Quarter 2991 3Rochester Medical Reports 31 25 Increase in Branded Sales Resulting in 9 25 Overall Sales Growth for the First Quarter 2991 4Rochester Medical Reports 31 25 Increase in Branded Sales Resulting in 9 25 Overall Sales Growth for the First Quarter 2991 5Rochester Medical Reports 31 25 Increase in Branded Sales Resulting in 9 25 Overall Sales Growth for the First Quarter 2991 6Rochester Medical Reports 31 25 Increase in Branded Sales Resulting in 9 25 Overall Sales Growth for the First Quarter 2991 7CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVTs Innovative Stent Coating Technology 2989 1CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVTs Innovative Stent Coating Technology 2989 2CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVTs Innovative Stent Coating Technology 2989 3
... - Hemispherx Biopharma,Inc. (AMEX: HEB) announce...of Immunology, April 2007) that explains the uniqu...mental therapeutic,Ampligen(R) (Poly I : Poly C(1...therapy for Chronic Fatigue Syndrome and as an,adj...eviewed study shows conclusively that the biologic...
...ontera AG announced,that an interim report regardi...atosis was received today from an independent revi...nvestigate the,efficacy and safety of several dose...nts received today refer to the clinical results,e...bout the results,after twelve weeks will follow. ,...
Other Medicine Technology:New Report Illuminates Ampligen's Unique Mechanism of Action 2New Report Illuminates Ampligen's Unique Mechanism of Action 3New Report Illuminates Ampligen's Unique Mechanism of Action 4
Recommended for aqueous samples of moderate viscosity and density. Proven ergonomic design reduces hand fatigue, prevents injury. Dry seal technology. No cleaning, no greasing. Volume Range (ul)
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,411-9) or contact custom
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL.
Our variable volume Finnpipette Techpette combines form and function in a high performance pipette. Advanced pipetting technology, plus a colour-coded volume range, ensures quality, safety, comfort a
Medicine Products: